1. Home
  2. RBOT vs KPTI Comparison

RBOT vs KPTI Comparison

Compare RBOT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vicarious Surgical Inc.

RBOT

Vicarious Surgical Inc.

HOLD

Current Price

$2.43

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.23

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RBOT
KPTI
Founded
2014
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.9M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
RBOT
KPTI
Price
$2.43
$7.23
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$7.00
$22.17
AVG Volume (30 Days)
134.2K
252.7K
Earning Date
11-12-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$3.51
52 Week High
$18.97
$12.45

Technical Indicators

Market Signals
Indicator
RBOT
KPTI
Relative Strength Index (RSI) 45.83 60.53
Support Level $1.81 $7.12
Resistance Level $2.33 $7.52
Average True Range (ATR) 0.23 0.48
MACD 0.07 0.04
Stochastic Oscillator 63.82 71.64

Price Performance

Historical Comparison
RBOT
KPTI

About RBOT Vicarious Surgical Inc.

Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: